Elmira Therapeutics

Elmira Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for rare endocrine and metabolic disorders. The company's primary focus is on the melanocortin-4 receptor (MC4R) pathway, which plays a critical role in regulating hunger and energy expenditure. Its lead candidate, ELM-001, is an investigational, orally administered small molecule MC4R agonist currently being evaluated for the treatment of Prader-Willi Syndrome (PWS). ELM-001 aims to alleviate hyperphagia, the life-threatening insatiable hunger that is a hallmark of PWS. Elmira is led by a management team with extensive experience in the development and commercialization of orphan drugs. The company is headquartered in Chicago, Illinois, and operates as a private entity.